SLC5A2 and type 2 diabetes mellitus: No clinically relevant changes in pharmacokinetic parameters have been observed in patients with T2D and mild or moderate hepatic impairment, and data from a large phase II–III trial have shown that SGLT2 inhibitors do not cause hepatotoxicity (11).